Evidence map›Paper›PMID 41659292›Full record

ArticleEJIFCC2026

Urgent Call for Action: Bridging Gaps in Asia-Pacific Laboratories' Transition to ISO 15189:2022.

Vivek Pant, Deepak Parchwani, Mayank Upadhyay, Ryunosuke Ohkawa, Mingma Lhamu Sherpa, Pradeep Kumar Dabla

Abstract read
In one paragraph

Article in EJIFCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vivek PantDepartment of Biochemistry, Samyak Diagnostic Pvt Ltd, Kathmandu, Nepal.
Deepak ParchwaniDepartment of Biochemistry, All India Institute of Medical Sciences, Rajkot, Gujarat, India.
Mayank UpadhyayAsia Pacific Regional Marketing Manager - Clinical Laboratory Assays for Quidel Ortho.
Ryunosuke OhkawaDepartment of Clinical Bioanalysis and Molecular Biology, Graduate School of Medical and Dental Sciences, Tokyo.
Mingma Lhamu SherpaDepartment of Biochemistry, Sikkim Manipal Institute of Medical Sciences, India.
Pradeep Kumar DablaDepartment of Biochemistry, G.B.Pant Institute of Postgraduate Medical Education & Research, Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ISO 15189:2022 introduces key updates to medical laboratory standards, emphasizing risk management, ethics, and technical competence. With the December 2025 deadline for ISO 15189:2012 to 15189:2022 transition nearing, a cross-sectional survey was conducted during the Asia-Pacific Federation of Clinical Biochemistry and Laboratory Medicine webinar on February 21, 2025, to assess readiness. On 303 total responses, awareness was high, with 85% familiar with the revised standard and 92% recognizing its stronger focus on risk management. Most (78%) viewed the transition as highly important, and 82% expected improvements in quality and patient care. Major barriers included financial constraints (65%), insufficient training (72%), and resistance to change (45%). Preparation efforts reported were gap analyses (68%), training programs (75%), and policy updates (70%). While optimism is strong, resource limitations and skills gaps threaten timely adoption. The findings highlight the urgent need for structured training, financial support, and expert guidance to help laboratories, particularly in resource-limited settings, meet the new requirements. Collaboration among laboratories, professional bodies, and regulatory authorities will be crucial to ensure a smooth and effective transition to ISO 15189:2022, enabling more accurate, reliable, and patient-centered diagnostics.

Indexed as

APFCB C-CP (Communication & Publications Committee)Asia-Pacific Federation of Clinical Biochemistry and Laboratory Medicine (APFCB)Clinical Laboratory DiagnosticsISO 15189:2022Lab QualityPatient Care

Identifiers

PMID41659292
PMCPMC12882077

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.